Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIER: Pola-R-CHP with or without intercalated high-dose methotrexate for DLBCL at high risk of CNS relapse
jRCTs031230505Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin and methotrexate in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
polatuzumab vedotinmethotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs031230505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230505.